Vertex Pharmaceutic (VRTX) Stock Price, Quote & News

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 341 6100

Website: www.vrtx.com

Address:

50 Northern Avenue, Boston, United States

BioTechHealthX Jul. 4 at 12:45 PM

$REGN $VRTX $NVO $ABBV $LLY From obesity drugs and diabetes treatments to CRISPR gene editing, mRNA cancer vaccines, biologics, and rare disease therapies, these 5 biotech stocks could be among the most exciting healthcare stocks to watch in today’s market. https://biotechhealthx.com/biotech-news/5-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/

0 · Reply

WAJeff Jul. 3 at 6:33 PM

#51-75 realized gainer changes: NXT to #51. $MRNA (169.59% ytd) rose to #56, $COHU (148.12% ytd) rose to #64 after a bunch sold at $74, $VRTX (16.21% ytd, this was a long hold for me and I likely sold way too early) is new at #71, $DCO (96.15% ytd) rose to #75.

0 · Reply

svertical1 Jul. 3 at 4:25 PM

$VRTX Excellent, but still too low…try a double. Yeah, Casgevy News is great, but the Vertex move is more about WS recalculating povetacicept (pove) as a strong best-in-class or highly competitive candidate in several of these indications: •IgA Nephropathy (IgAN) •Lupus Nephritis (LN) and ANCA-Associated Vasculitis (AAV) •Generalized Myasthenia Gravis

1 · Reply

Doozio Jul. 3 at 4:16 PM

$VRTX da huckleberries are thru da $$$ because it was always ENTA 🐒🍌🧠⏰♾️

0 · Reply

cwEWF Jul. 3 at 10:14 AM

$VRTX continue rally in ((3)) after expected pullback in ((2)) earlier in March-2026 update It already broke to new high in weekly after ((2)) ended at 412.27 low Above May-2026 low, pullback remain supported & buyers remain in control. #Elliottwave

0 · Reply

ForRealz325 Jul. 3 at 9:51 AM

$LPT.X $ORAI.X $TOS.X $VRTX 💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰 https://x.com/TokenOS_AI/status/2072892441548722603?s=20 Utilizing this data, the network staking is currently paying out a 26% APY! That’s completely unheard of and not standard for staking yield. ⚠️ At 28M Market cap, this also implies that the market is undervaluing $TOS.X . Most DePin Ai projects are trading at 3X-8X net profits (minimum base case) some even more! Based on actual profits (not speculation), from this price, that’s a 3X-8X measured moved (base case). 10X-15X measured move is extremely possible here based on current &amp; real supply shock dynamic and extremely constrained liquidity pools.

0 · Reply

ForRealz325 Jul. 3 at 2:20 AM

$TOS.X * $VRTX * $ORAI.X (Oraichain) * $LPT.X (Livepeer

0 · Reply

BullEngine Jul. 2 at 10:09 PM

Gene editing still looks early, and $VRTX / $CRSP keep the spotlight on CASGEVY. The first approved CRISPR therapy has already shown real traction in sickle cell, and each new FDA step adds more credibility to the story. $XBI stays in focus as the sector narrative builds.

0 · Reply

SmartAlphaa Jul. 2 at 9:59 PM

$CRSP $VRTX FDA clears Casgevy for kids 2+ with sickle cell disease. New label opens the therapy to a younger patient group and expands the market.

0 · Reply

BullNavigatorr Jul. 2 at 9:56 PM

$CRSP $VRTX FDA clears Casgevy for kids 2+ with sickle cell disease. New label opens the therapy to a younger patient group and expands the market.

0 · Reply

Vertex announces FDA approval for expanded use of Casgevy

Jul 1, 2026, 7:58 PM EDT - 2 days ago

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Jul 1, 2026, 6:45 PM EDT - 2 days ago

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

Jun 24, 2026, 7:41 AM EDT - 10 days ago

3 Companies Redefining Healthcare Innovation

CMPS CRSP

Jun 11, 2026, 7:14 AM EDT - 23 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

2026-06-11T09:22:17.000Z - 23 days ago

Vertex Pharmaceuticals presents new data on Casgevy at EHA

Jun 11, 2026, 2:01 AM EDT - 23 days ago

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Jun 10, 2026, 11:20 AM EDT - 24 days ago

Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-05T16:05:11.000Z - 4 weeks ago

Vertex Pharmaceuticals presents data on ALYFTREK in children with CF

Jun 5, 2026, 12:00 PM EDT - 4 weeks ago

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Jun 3, 2026, 4:00 PM EDT - 4 weeks ago

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

2026-06-01T12:42:04.000Z - 4 weeks ago

Vertex announces U.S. FDA accepted BLA submission for povetacicept

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

May 29, 2026, 9:00 AM EDT - 5 weeks ago

Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference

2026-05-27T09:22:01.000Z - 5 weeks ago

Vertex Pharmaceuticals assumed with a Buy at Truist

2026-05-21T17:00:12.000Z - 6 weeks ago

Vertex announces Health Canada acceptance of NDS for suzetrigine

May 19, 2026, 2:35 PM EDT - 6 weeks ago

Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Vertex to Participate in Upcoming May Investor Conferences

2026-05-07T10:11:22.000Z - 2 months ago

Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays

2026-05-07T07:48:12.000Z - 2 months ago

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

May 6, 2026, 7:01 AM EDT - 2 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

2026-05-05T12:54:50.000Z - 2 months ago

Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley

2026-05-05T11:48:44.000Z - 2 months ago

Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital

2026-05-05T10:49:13.000Z - 2 months ago

Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord

2026-05-05T10:47:35.000Z - 2 months ago

Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein

SION

2026-05-04T22:25:16.000Z - 2 months ago

Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals

MRNA

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Slides: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

Vertex Pharmaceuticals Quarterly report: Q1 2026

2026-05-04T20:08:07.000Z - 2 months ago

Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31

2026-05-04T20:07:54.000Z - 2 months ago

Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B

May 4, 2026, 4:04 PM EDT - 2 months ago

Vertex tops profit estimates as sales of new cystic fibrosis drug surge

May 4, 2026, 4:01 PM EDT - 2 months ago

Vertex Reports First Quarter 2026 Financial Results

2026-05-04T18:46:06.000Z - 2 months ago

Notable companies reporting after market close

DUOL GRAB ON PGR PINS PLTR PSKY

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 4:00 PM EDT - 3 months ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Vertex Pharmaceuticals Proxy statement: Proxy filing

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Mar 18, 2026, 2:23 PM EDT - 3 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 11, 2026, 11:30 AM EDT - 4 months ago

Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:22 PM EDT - 4 months ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 10:54 AM EDT - 4 months ago

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:00 AM EDT - 4 months ago

Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:13 PM EDT - 4 months ago

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:02 PM EDT - 4 months ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 5, 2026, 4:00 PM EST - 4 months ago

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 10:00 AM EST - 4 months ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 3, 2026, 9:10 AM EST - 4 months ago

Vertex Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 17, 2026, 4:00 PM EST - 4 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

Vertex Pharmaceuticals Slides: Q4 2025

Feb 12, 2026, 4:06 PM EST - 5 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:01 PM EST - 5 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 2, 2026, 10:08 PM EST - 5 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Jan 22, 2026, 1:19 PM EST - 5 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Jan 20, 2026, 4:00 PM EST - 5 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 12, 2026, 5:15 PM EST - 6 months ago

Vertex Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 6 months ago

Vertex Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:00 PM EST - 6 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Dec 22, 2025, 4:00 PM EST - 6 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 6, 2025, 7:04 AM EST - 7 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:01 AM EST - 7 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 3, 2025, 9:00 AM EST - 7 months ago

Vertex Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Nov 19, 2025, 4:00 PM EST - 8 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 11, 2025, 10:15 AM EST - 8 months ago

Vertex Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 8, 2025, 8:00 PM EST - 8 months ago

Vertex Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 8:00 PM EST - 8 months ago

Vertex Pharmaceuticals Slides: Study Update

Nov 8, 2025, 5:15 PM EST - 8 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 4, 2025, 1:22 PM EST - 8 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Nov 3, 2025, 4:30 PM EST - 8 months ago

Vertex Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Vertex Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Vertex Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Vertex Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:20 PM EST - 8 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:02 PM EST - 8 months ago

Vertex Reports Third Quarter 2025 Financial Results

Oct 27, 2025, 4:00 PM EDT - 8 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 23, 2025, 9:00 AM EDT - 9 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 17, 2025, 9:04 AM EDT - 9 months ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 6, 2025, 4:00 PM EDT - 9 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 2, 2025, 1:31 PM EDT - 9 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

Sep 25, 2025, 7:45 AM EDT - 10 months ago

Vertex Announces Key Advancements Across Kidney Portfolio

Sep 23, 2025, 9:00 AM EDT - 10 months ago

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Sep 23, 2025, 3:10 AM EDT - 10 months ago

Vertex Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2025

Sep 18, 2025, 8:30 AM EDT - 10 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Sep 11, 2025, 9:05 AM EDT - 10 months ago

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 9, 2025, 11:30 AM EDT - 10 months ago

Vertex Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 1:47 PM EDT - 10 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST

Sep 3, 2025, 11:00 AM EDT - 10 months ago

Vertex Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 9:00 AM EDT - 10 months ago

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Aug 20, 2025, 4:00 PM EDT - 11 months ago

Vertex to Participate in Upcoming September Investor Conferences

Aug 5, 2025, 10:25 AM EDT - 11 months ago

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Aug 4, 2025, 5:40 PM EDT - 11 months ago

Vertex tops estimates on cystic fibrosis treatment strength, new products

BioTechHealthX Jul. 4 at 12:45 PM

0 · Reply

WAJeff Jul. 3 at 6:33 PM

0 · Reply

svertical1 Jul. 3 at 4:25 PM

1 · Reply

Doozio Jul. 3 at 4:16 PM

$VRTX da huckleberries are thru da $$$ because it was always ENTA 🐒🍌🧠⏰♾️

0 · Reply

cwEWF Jul. 3 at 10:14 AM

0 · Reply

ForRealz325 Jul. 3 at 9:51 AM

0 · Reply

ForRealz325 Jul. 3 at 2:20 AM

$TOS.X * $VRTX * $ORAI.X (Oraichain) * $LPT.X (Livepeer

0 · Reply

BullEngine Jul. 2 at 10:09 PM

0 · Reply

SmartAlphaa Jul. 2 at 9:59 PM

$CRSP $VRTX FDA clears Casgevy for kids 2+ with sickle cell disease. New label opens the therapy to a younger patient group and expands the market.

0 · Reply

BullNavigatorr Jul. 2 at 9:56 PM

$CRSP $VRTX FDA clears Casgevy for kids 2+ with sickle cell disease. New label opens the therapy to a younger patient group and expands the market.

0 · Reply

StocktwitsNews Jul. 2 at 9:16 PM

CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up $CRSP $VRTX https://stocktwits.com/news/equity/markets/crsp-vrtx-stocks-surge-as-fda-clears-casgevy-for-children-ages-2-and-up/cZmexkXR7je

0 · Reply

TannerTDB Jul. 2 at 9:13 PM

$VRTX BREAKING out thanks to the FDA $CRSP news.

0 · Reply

Gostrongx Jul. 2 at 8:35 PM

$CRSP $VRTX guess the announcement gave VRTX a bigger boost

0 · Reply

judgeyoung2 Jul. 2 at 7:27 PM

$VRTX i drank two red bulls and i’m upping my price target to $600 by end of July.

0 · Reply

StreakGeek Jul. 2 at 5:42 PM

$TAK $FICO $INFY $VRTX that's

0 · Reply

judgeyoung2 Jul. 2 at 4:38 PM

$VRTX needs to cut through with conviction

0 · Reply

JerryMalone32 Jul. 2 at 4:31 PM

$CRSP does anyone have access to today’s STAT News interview of David Meek, who said they (Genetix/Bluebird) are the Sickle Cell market leaders and $VRTX is #2 and falling further behind? Thanks

1 · Reply

ntbd618 Jul. 2 at 3:43 PM

$VRTX breaking out the 2 year platform.

0 · Reply

michie Jul. 2 at 3:02 PM

$VRTX still waiting to buy

0 · Reply

svertical1 Jul. 2 at 2:46 PM

$VRTX Nice chart! Breakout in realtime!

0 · Reply

kagrawala Jul. 2 at 2:44 PM

$VRTX finally - back to 2024 prices. Hopefully goes to 600+ with good pipeline news. Long term hold for me - average price of ~210.

1 · Reply

Whiskeyunderthebed Jul. 2 at 2:43 PM

$LRCX I'm defintely all over this drop-just sold all my $VRTX and going in here shortly.

0 · Reply

Market Cap	134.02B
Revenue (ttm)	12.00B
Net Income (ttm)	3.95B
EPS (ttm)	N/A
PE Ratio	29.61
Forward PE	29.27
Profit Margin	32.94%
Debt to Equity Ratio	0.00

Volume	1,855,900
Avg Vol	1,493,710
Day's Range	N/A - N/A
Shares Out	253.81M
Stochastic %K	99%
Beta	0.29
Analysts	Strong Sell
Price Target	$548.07